SQUID Liquid Embolic Agent (LEA)
Balt USA, LLC · Decision date Jan 30, 2026
What did the FDA approve?
FDA approved the SQUID Liquid Embolic Agent from Balt USA, LLC on January 30, 2026. The approval covers embolization of the middle meningeal artery as an adjunct to usual care in patients with symptomatic chronic subdural hematoma measuring 10 mm or greater in thickness, when a neurosurgeon determines an intervention is necessary.
The database record lists the device category as neurovascular liquid embolic agent, the specialty as neurology, and the product code as SGU. The record does not include a supplement type or supplement reason, so no additional change to a prior approval is described. The statement reports an intended use; it does not independently establish safety or clinical effectiveness.
FDA approval order statement
The SQUID Liquid Embolic Agent is indicated for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with symptomatic chronic subdural hematoma(s) (SDH) measuring 10 mm or greater in thickness in whom an intervention is deemed necessary as determined by a neurosurgeon.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Jan 30, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250009
- Regulatory pathway
- Premarket approval application
- Applicant
- Balt USA, LLC
- Product code
- SGU
- Decision code
- APPR
- Decision date
- Jan 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Neurovascular Liquid Embolic Agent.
- Applicant
- Balt USA, LLC
- Product code
- SGU
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250009 received
Application receipt date recorded by FDA.
P250009 · FDA decision
APPR
P250009/S002 · Related supplement
SQUID Liquid Embolic Agent (LEA)
P250009/S001 · Related supplement
SQUID Liquid Embolic Agent (LEA)
Timeline entries are records held by MedtechLedger for P250009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SQUID Liquid Embolic Agent (LEA)P250009/S002 | Balt USA, LLC | PMA supplement | Sep 9, 2026 | FDA |
SQUID Liquid Embolic Agent (LEA)P250009/S001 | Balt USA, LLC | PMA supplement | Oct 16, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Balt USA, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 29 Parker, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P250009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
